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incidence
Breast cancer is the most common cancer in women in many
countries, including developing countries. In 2006, the crude
incidence in the European Union was 109.8/100 000, and the
mortality was 38.4/100 000 women/year. In 2008, 1.38 million
new cases and 458 000 breast cancer deaths were noted in the
world. Since 1990 the incidence rate has increased 1.5% annually.
Due to advances both in early detection and in adjuvant
treatment, mortality rates from breast cancer have been
decreasing steadily in most Western countries since the early
1990s. However, it is still the leading cause of cancer mortality in
women. Approximately 4–6% of breast cancers are metastatic at
diagnosis; of those approximately one-fifth will survive 5 years.
Depending on prognostic factors, in the worst-case scenario, up
to 30% of node-negative and up to 70% of node-positive breast
cancers will relapse. The prevalence of metastatic disease is high
because many women live with the disease for several years.
diagnosis
Clinical suspicion must be confirmed by imaging (including
functional imaging such as positron emission tomography-
computed tomography (PET-CT) or dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI); additional
information may be provided by laboratory tests.
Efforts should be made to obtain histopathological
confirmation particularly in the situation of an isolated
metastatic lesion. Biological markers important for treatment
decisions, such as hormone receptor (HR) and HER2 status,
should be evaluated in the metastatic lesion whenever possible.
Although there are no data to support the choice of therapy in
the case of discordance in HR/HER2 status between primary and
metastatic tumor, retrospective data suggest an inferior outcome
in ‘discordant’ patients (possibly due to inappropriate treatment,
not adjusted for biomarker changes). Biopsy may potentially
be avoided (i) in situations where the procedure is too risky;
(ii) in cases where the time elapsed between the primary tumor and
the metastatic disease diagnosis is relatively short (<1–2 years);
(iii) or when the results of the biopsy are unlikely to change
the therapeutic attitude (e.g. pre-existent contraindications for the
use of chemotherapy or anti-HER2 therapies).
There is no proven value of routine diagnostic tests
‘screening’ for metastatic disease in asymptomatic early breast
cancer patients. However, the available data are from a time
when neither biological therapy nor efficacious (in terms of
local control) and less invasive (in terms of quality of life and
side effects) locoregional techniques, such as radiosurgery for
central nervous system (CNS) metastases or radiofrequency
ablation for liver metastases, were available. Additionally, new
techniques are now available, such as MRI, PET-scan, PET-CT,
circulating tumor cells and others, that may allow the detection
of very early metastatic disease. Therefore, new studies are
needed to evaluate the role of early diagnosis of metastatic
disease in this new context.
Locoregional recurrence is often associated with distant
spread, and such patients should undergo full staging
procedures before undergoing local treatments.
staging and prognosis assessment
 Complete history, including
(i) menopausal status and co-morbidities;
(ii) detailed history of the primary tumor, its biology,
management and status at last follow-up;
(iii) history of recurrent/metastatic disease including
duration, previous sites of involvement, previous
treatments and their effect;
(iv) current symptoms, performance status, socio-
economic background and preferences (Table 1).
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 Detailed physical examination.
 Blood tests: complete blood count, liver and renal function
tests, alkaline phosphatase, calcium and, if applicable, specific
tests required for particular treatments such as urinary
protein. The clinical value of tumor markers has not been
proven. However, they may assist in evaluating response to
treatment particularly in patients with non-measurable
disease.
 Chest X-ray or CT, or abdominal ultrasound, CT or MRI
should be used to identify visceral disease.
 Bone scintigraphy, with confirmation of lesions by X-ray/CT/
MRI.
 CT and/or MRI of the CNS should be symptom driven.
 PET/PET-CT may be useful for identifying the site of relapse,
particularly when traditional imaging methods are equivocal
or conflicting. It may also be helpful to identify or confirm
the situation of an isolated locoregional relapse or metastatic
lesion, since this subset of patients may benefit from a more
aggressive multidisciplinary approach.
 Estrogen receptor (ER), progesterone receptor (PgR), HER2
receptors and proliferation markers of the metastatic lesion
should be obtained, if possible, and particularly if not
available on the primary tumor.
 Cardiac assessments, in particular in HER2+ patients and
patients eligible for anthracycline-based chemotherapy.
 Circulating tumor cells is still an experimental technique and
should not be used outside a clinical trial.
 In the case of lesions inaccessible for biopsy, functional
imaging such as PET-CT or DCE-MRI may be helpful to
confirm their malignant character.
treatment—general statements:
locoregional recurrence
 Isolated locoregional recurrence should be treated like a new
primary with a curative intent. If feasible, complete excision
of recurrent tumor is recommended. In patients previously
treated with breast-conserving surgery, a mastectomy should
be performed when feasible. In patients not exposed to
postoperative irradiation, full dose radiotherapy to the chest
wall and (when indicated) regional lymph node areas should
be given. In those previously irradiated, the value of re-
irradiation is not proven; however, re-irradiation to limited
areas in the chest wall may be applied, after a careful benefit–
risk balance, taking into consideration the duration of the
radiation-free period, intensity of postradiotherapy changes
and the risk of additional locoregional relapse. Inoperable
patients can, if it is feasible, undergo radical radiotherapy to
chest wall and regional lymph node areas with boost to
macroscopic disease sites. However, in these patients, primary
systemic therapy to decrease the size of the tumor and render
it operable should be the first choice.
 The value of ‘secondary or pseudo-adjuvant’ systemic
treatment is not well proven. The role of chemotherapy in
this setting is a subject of ongoing randomized studies [II, B].
These studies have been very hard to run due to poor accrual,
and this question might therefore remain unanswered.
Factors such as tumor aggressiveness, previous adjuvant
systemic therapy received, the patient’s co-morbidities and
preferences should all be taken into account when deciding to
propose or not ‘pseudo-adjuvant’ chemotherapy (expert
opinion). Although unproven, ‘pseudo-adjuvant’ endocrine
therapy is a common practice in the case of HR+ tumors and
is acceptable in view of its predicted benefit and low toxicity
(expert opinion). ‘Pseudo-adjuvant’ trastuzumab therapy is
also acceptable in cases where adjuvant trastuzumab was not
prescribed due to unavailability at the time of initial diagnosis
and if no contraindications exist (expert opinion).
metastatic disease
 The management of metastatic breast cancer (MBC) should
involve all appropriate specialties in a multi-/interdisciplinary
team (medical, radiation, surgical and imaging oncologists,
palliative care specialist, psychosocial support), and patients
should be offered personalized appropriate psychosocial,
supportive and symptom-related interventions as a routine
part of their care. Specialist breast nurses can provide crucial
support to patients with advanced breast cancer and should
be available to all patients. Countries in which this nurse
subspecialty does not yet exist should make every effort to
establish it.
 There are few proven standards of care in MBC management;
therefore, well-designed, independent, prospective
randomized trials are a priority. Additionally, participation in
such clinical trials should be offered to all eligible patients,
whenever available.
 The vast majority of MBC is incurable, and hence the main
treatment goal is palliation, with the aim of maintaining/
improving quality of life, and possibly improving survival.
 The realistic treatment goals should be discussed with the
patient and her/his family from the beginning and the patient
should be encouraged to actively participate in all decisions.
Patients’ preferences should always be taken into account.
Table 1. Factors to consider in risk assessment and treatment decision
making for MBC
Disease-related factors Patient-related factors
Disease-free interval Patient’s preferences
Previous therapies and response Biological age
Biological factors (hormonal
receptors, HER2)
Menopausal status
Tumor burden (number and site
of metastases)
Co-morbidities and performance
status
Need for rapid disease/
symptom control
Socio-economic and
psychological factors
Available therapies in the
patient’s country
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 Co-ordination and continuity of care may be facilitated by
a specialist breast care nurse or equivalent.
 Systemic treatment options for MBC are endocrine therapy,
chemotherapy and biological agents such as trastuzumab,
bevacizumab and lapatinib [I, A].
 The choice of therapy should be made after consideration of
the factors listed in Table 1
 Patients’ preferences should always be taken into account not
only about treatment options but also methods of treatment
administration (intravenous or oral).
 For the majority of patients, overall survival outcomes from
sequential use of single cytotoxic drugs are equivalent to
combination chemotherapy. The choice between both these
options should primarily take into account the need for
a rapid and significant response and quality of life.
 Duration of each regimen and number of regimens should be
tailored to each individual patient.
 Radiation therapy is an integral part of palliative treatment.
The most common indications for palliative radiotherapy
include:
s bone metastases which are painful or carry a risk of
fracture and/or neurological complications
(radiotherapy options include ‘limited field’ external
beam irradiation, hemi-body irradiation and
application of radioactive ‘bone-seeking’ isotopes);
s brain metastases. In patients with single or few metastatic
foci, stereotactic radiosurgery can be used as an
alternative to surgical resection, with improvement in
local control and fewer side effects than whole brain
radiotherapy;
s painful or fungating soft tissue masses.
 For limited metastatic presentations, surgery or radical
radiotherapy may be considered. Although no randomized
data exist, the bulk of retrospective data suggests a significant
survival benefit from the removal of the primary tumor in
patients with metastatic disease. Prospective randomized
trials addressing this question are currently ongoing.
 Bisphosphonates should be used for the treatment of
hypercalcemia and clinically evident bone metastases
(to palliate symptoms and decrease risk of bone events)
[I, A]. Bisphosphonates should start following a diagnosis
of bone metastases. Although the timing and optimal
duration of bisphosphonate treatment are unknown and the
benefit of duration beyond 2 years has not yet been
demonstrated in clinical trials, ongoing risk of skeletal
events persists, especially at times of disease progression,
and long-term treatment seems wise. The impact of
bisphosphonate-associated side effects (including
osteonecrosis of the jaw and nephrotoxicity) is minor, and
for the vast majority of patients the benefit of treatment
outweighs the risks. Recent studies demonstrated superior
activity and a favorable toxicity profile of the RANK-ligand
antibody denosumab in breast cancer-related bone disease
and hopefully this compound will become generally available
for this indication soon.
 The choice of drugs, their timing, optimal duration, methods
of administration and side effects should be considered
individually, taking into account predicted treatment
acceptability and adherence. Availability and reimbursement
issues must also be taken into account.
treatment—specific breast cancer
subtypes
patients with luminal-type breast cancer (HR-
positive breast cancer, irrespective of HER2 status)
 Endocrine therapy is the preferred option except if clinically
aggressive disease mandates a quicker response or if there are
doubts regarding the endocrine responsiveness of the tumor.
Available endocrine agents are listed in Table 2.
 The choice of endocrine agent should be individualized
according to the drug safety profile, co-morbidities, tumor
biology and agents received in the adjuvant setting.
 Apart from combination with ovarian suppression in
premenopausal patients, there is no rationale for use of
combination hormonal therapies.
 The value of maintenance with hormonal treatment after
chemotherapy has not been confirmed by controlled clinical
studies, but is a reasonable approach.
 Concomitant chemo-hormonal therapy is discouraged.
 In the case of HER2 overexpression/amplification addition of
anti-HER2 therapies to hormonal treatment is beneficial.
premenopausal patients. If no prior adjuvant tamoxifen was
given or if it has been discontinued for >12 months: tamoxifen
with ovarian ablation (luteinizing hormone-releasing hormone
analog or surgery) is the preferred option [I, B]. Otherwise,
third-generation aromatase inhibitors may be considered after
or concomitantly with ovarian ablation. Further treatment lines
(in patients who have undergone ovarian ablation/suppression)
do not differ from those used in the postmenopausal
population (as described below).
postmenopausal patients. If no prior adjuvant third-generation
aromatase inhibitors (anastrozole, letrozole or exemestane)
Table 2. Available endocrine therapies for MBC
Class of agent
Selective estrogen receptor
modulators
Tamoxifen; toremifene
Estrogen receptor down-
regulator
Fulvestrant
Luteinizing hormone-
releasing hormone analogs
Goserelin; leuprorelin
Third-generation aromatase inhibitors
Non-steroidal Anastrozole, letrozole
Steroidal Exemestane
Progestins Medroxyprogesterone
acetate; megestrol acetate
Anabolic steroids Nandrolone decanoat
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were given or if they have been discontinued for >12 months
these are the preferred option since they have consistently
shown superior results to tamoxifen as first-line therapy in
terms of response rate, time to progression and, for letrozole, in
2-year overall survival [II, A]. Caution should be given to the
risk of accelerated bone loss in these patients, and calcium and
vitamin D supplements are recommended.
Tamoxifen remains an acceptable first-line therapy. Albeit
definitive data are still needed, it seems reasonable to advise
patients under tamoxifen to avoid, whenever possible, the use of
drugs modulating the activity of CYP2D6, such as some selective
serotonin reuptake inhibitor antidepressants (paroxetine,
fluoxetine). Fulvestrant has also shown value as first-line therapy
after progression on adjuvant aromatase inhibitors.
Second- and further lines of hormone therapy may include
tamoxifen, third-generation aromatase inhibitors (if not
previously used), fulvestrant, megestrol acetate and androgens.
No definitive recommendation can be given for endocrine
treatment cascade and, in particular, the best option after
progression on a third-generation aromatase inhibitor is
currently unknown.
Patients with clear evidence of endocrine resistance should be
offered chemotherapy or participation in clinical trials. No
overall recommendation can be made regarding the number of
lines of endocrine therapy which should be given before
switching to chemotherapy since this is highly variable and
dependent on various factors such as intensity and duration of
response to previous endocrine therapies, presence or absence
of symptoms and/or rapidly progressive or life-threatening
disease, patient performance status and estimated capacity to
tolerate chemotherapy, among others
patients with ‘triple negative’ breast cancer
(HR-negative and HER2-non-overexpresed/
non-amplified breast cancer)
 Patients having HR-negative tumors are candidates for cytotoxic
chemotherapy. Available agents/regimens are listed in Table 3.
 The only standard of care with level 1 evidence is the use of
a taxane-based regimen as first-line therapy in patients
progressing after adjuvant anthracycline-based chemotherapy
[I, A]. The selection of the best agent/regimen should be
individualized and should take into account the factors listed in
Table 1.
 For the majority of patients, overall survival outcomes from
the sequential use of single cytotoxic drugs is equivalent to
that of combination chemotherapy, with less associated
toxicity and better quality of life. Therefore, in the absence of
the need for a rapid and significant response for symptom
control or life-threatening disease, preference should be given
to the sequential use of a sequential single cytotoxic agent
approach. However, very few randomized clinical trials have
correctly addressed this question and there is an urgent need
for a well-designed, prospective randomized trial to compare
sequential single-agent with combination chemotherapy as
first-line therapy of MBC. In triple negative disease, because
of frequent visceral involvement, aggressive course and risk of
rapid patient deterioration, combination chemotherapy is
often required. Notwithstanding the above, all factors should
be taken into account, and triple negative biology on its own
does not always require combination chemotherapy as shown
by data from trials where patients with this subtype of breast
cancer, but without extensive or life-threatening disease, were
treated successfully with single agent chemotherapy.
 There is no standard approach for patients requiring
second- or further line treatment since there are few data
supporting the superiority of any particular regimen.
 Duration of each regimen and number of regimens should be
tailored to each individual patient. Continuing beyond
third-line treatment may be justified in patients with good
performance status and response to previous chemotherapy.
 High-dose chemotherapy should not be proposed.
patients with HER-2-positive (overexpressed/
amplified) breast cancer
 Patients should be treated with trastuzumab with or without
chemotherapy [II, B].
Table 3. Selection of available chemotherapy agents/regimens for MBC
Non-anthracycline-containing
Cyclophosphamide/methotrexate/fluorouracil (CMF)
Platinum-based combinations (e.g. cisplatinum + 5-fluorouracil;
carboplatin + gemcitabine)
Capecitabine
Vinorelbine
Gemcitabine
Capecitabine + vinorelbine
Vinorelbine 6 gemcitabine
Oral cyclophosphamide with or without methotrexate (metronomic
chemotherapy)
Anthracycline-containing
Doxorubicin or epirubicin monotherapy (weekly or 3-weekly)
Doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide
Liposomal doxorubicin with or without cyclophosphamide
Fluorouracil/doxorubicin/cyclophosphamide
Fluorouracil/epirubicin/cyclophosphamide
Taxane-containing
Paclitaxel monotherapy weekly
Docetaxel monotherapy 3-weekly or weekly
Doxorubicin/taxane (paclitaxel or docetaxel)
Epirubicin/taxane (paclitaxel or docetaxel)
Docetaxel/capecitabine
Paclitaxel/gemcitabine
Paclitaxel/vinorelbine
Paclitaxel/carboplatin
New cytotoxic agents
Eribulin
Ixabepilone
Abraxane (nab-paclitaxel)
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 Trastuzumab should be offered early to all HER2-positive
MBC patients.
 Cardiac monitoring should be performed before and while on
trastuzumab therapy.
 The bulk of retrospective data and results of a phase III
randomized trial show that continuing trastuzumab,
associated with a different chemotherapy regimen, after the
first disease progression is superior to the discontinuation of
this agent. The benefit of continuing anti-HER2 therapy
beyond first progression is based on fewer data, but available
evidence points to the continuation of anti-HER2 therapy for
as long as possible.
 Lapatinib has shown a significant increase in time to
progression in combination with capecitabine in patients
progressing after trastuzumab, anthracyclines and taxanes.
The question of continuing trastuzumab or changing to
lapatinib at the time of first progression remains open.
 Combination of trastuzumab and lapatinib seems to be superior
to lapatinib monotherapy in patients progressing on
anthracyclines, taxanes and trastuzumab, albeit not yet approved.
 Addition of anti-HER2 agents (trastuzumab or lapatinib)
to endocrine therapy allows for prolongation of progression-
free survival (PFS) and may be a viable option for some
patients with ER/PgR-positive and HER2-positive tumors
who are evaluated as not needing or not being able to tolerate
chemotherapy with anti-HER2 therapy. The potential side
effects of the available combinations of endocrine agents and
anti-HER-2 agents should be discussed with the patient.
 Other anti-HER-2 or pan-anti-HER agents, such as
pertuzumab, trastuzumab-DM1 and HKI-272, are currently
under investigation, as are combinations of trastuzumab with
other biological agents with or without chemotherapy to
tackle the problem of resistance to trastuzumab.
other biological agents
 Bevacizumab, an antiangiogenic agent, has been approved by
the Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA) for use in combination with
paclitaxel as first-line treatment of MBC after showing
a benefit of 6 months in PFS in the ECOG 2100 study. In two
other randomized phase III trials, the AVADO and RIBBON
studies, and in a meta-analysis of phase III randomized trials,
the benefit of bevacizumab in an unselected breast cancer
population was of 1 month in PFS at the cost of increased
toxicity and with no significant benefit in overall survival. For
this reason, the FDA recommended removing the breast
cancer indication for bevacizumab because of an unfavorable
efficacy–safety profile. In Europe, however, bevacizumab
remains approved, only as first-line therapy and only in
combination with paclitaxel, and may be considered for
carefully selected patients with limited treatment options,
requiring a well thought out balance between side effects,
benefits and costs.
 Sunitinib, another antiangiogenic agent, both as single agent
and in combination with chemotherapy, failed to show
a significant benefit in unselected MBC populations and
should not be used outside clinical trials. Additionally, certain
tyrosine kinase inhibitors (i.e. gefitinib and erlotinib) have
also not yielded significant benefit for MBC.
 Efforts must continue to be made to identify which patients
may benefit from the antiangiogenic approach.
 PARP [poly (ADP-ribose) polymerase] inhibitors have shown
promising results, in phase II trials, as single agents in BRCA-
mutated MBC and in combination with carboplatin and
gemcitabine in unselected triple negative MBC patients.
However, a large phase III trial evaluating iniparib in
combination with carboplatin and gemcitabine in unselected
triple negative MBC failed to show the expected benefit.
Other PARP inhibitors and other combinations are still under
evaluation in clinical trials.
 Several other biological or targeted agents are currently under
active investigation as single agents or in combination.
response evaluation
 Response evaluation is routinely recommended after 2–3
months of endocrine therapy and after two or three cycles of
chemotherapy by clinical evaluation, subjective symptom
evaluation, blood tests and repeating the initially abnormal
radiological examinations with comparative measures.
However, the interval between assessments should be tailored
to the clinical needs of the patient and to the aggressiveness of
the disease. In the case of clinical suspicion of progressive
disease, appropriate tests (imaging and laboratory) should be
performed irrespective of scheduled examinations, if
necessary including areas not imaged in previous tests.
 Bone scans should be used with extreme caution and only if
other imaging tests are unavailble to assess response in bone
due to the potential for a flare response being confused with
progression.
 Serum tumor markers (such as CA 15-3 and/or CEA) may be
helpful in monitoring response, particularly in the case of not
easily measurable disease, but should not be used as the only
determinant for treatment decision.
 The role of PET/PET-CT in response assessment is still under
investigation, but it may be used to determine disease
progression.
 Maintenance of a good quality of life is paramount and can
best be achieved with prompt amelioration of symptoms
and side effects of treatment. Psychometrically sound,
well-validated questionnaires are available to measure
patient-reported outcomes (PROs). These should be employed
regularly to help assess the impact of treatment and to monitor
symptoms that demand supportive intervention promptly.
follow-up
 Follow-up after the treatment of locoregional recurrence may
be carried out as for primary breast cancer.
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 Patients with MBC must be seen frequently enough to
provide best possible palliation of symptoms and quality of
life, which means on average every 2–3 months if on
endocrine therapy and every one or two cycles of
chemotherapy. If progression is suspected (due to
aggravation or appearance of new signs/symptoms and/or
significant increase in the levels of tumor markers), response
evaluation should be done immediately.
 There is no defined optimal visit schedule for MBC patients
in disease remission and no active treatment; however, apart
from scheduled visits these patients should be instructed to
contact their physician immediately in case of symptoms
suggestive of progressive disease or treatment complications.
 Patients need good quality information and a care plan
outlining all aspects of treatment and care, clarification of the
purpose of different treatments, their side effects and
potential impact on functional, emotional and social well-
being.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
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